About IgGenix
IgGenix is a company based in San Francisco (United States) founded in 2019 by Stephen Quake and Kari Nadeau. IgGenix has raised $75 million across 3 funding rounds from investors including Lilly, ARE and Khosla Ventures. IgGenix offers products and services including IGNX001 and SEQ SIFTER. IgGenix operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter San Francisco, United States
- Founders Stephen Quake, Kari Nadeau
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Iggenix, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$75 M (USD)
in 3 rounds
-
Latest Funding Round
$40 M (USD), Series B
Feb 06, 2023
-
Investors
Lilly
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of IgGenix
IgGenix offers a comprehensive portfolio of products and services, including IGNX001 and SEQ SIFTER.
Injectable treatment that blocks allergic reactions for peanut allergy
RNA-sequencing tool for identifying rare antibodies in human blood samples
People of IgGenix
Unlock access to complete
Funding Insights of IgGenix
IgGenix has successfully raised a total of $75M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $40 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in IgGenix
IgGenix has secured backing from 7 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Lilly, ARE and Khosla Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage startups are funded by this venture capital firm.
|
Locked | Locked | Locked | |
|
Venture capital investments are focused on food allergy solutions.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for IgGenix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by IgGenix
Investment portfolio details for IgGenix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - IgGenix
Detailed financials for IgGenix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Iggenix Comparisons
Peer comparison for IgGenix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of IgGenix
IgGenix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of IgGenix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Iggenix
Complete news archive for IgGenix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about IgGenix
IgGenix was founded in 2019 and raised its 1st funding round 1 year after it was founded.
IgGenix is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
IgGenix is a funded company, having raised a total of $75M across 3 funding rounds to date.
IgGenix was founded in 2019 and is based in San Francisco, United States. Operations focus on the biotechnology sector, where antibody-based therapeutic platforms are developed to address food allergies. Single-cell genomic technology is utilized to analyze rare human B cells that bind allergens. Immune-modulating activities from the IgG antibody class are incorporated to suppress allergic reactions and monitor conditions.
IgGenix's top competitors include Spark Therapeutics, BridgeBio and argenx.
IgGenix offers IGNX001 and SEQ SIFTER.
IgGenix has 7 investors. Key investors include Lilly, ARE, Khosla Ventures, AllerFund, and Sean Parker.